Medisan(SZ:002900)2024-07-09 11:25Financial Performance - The estimated net profit for the first half of 2024 is projected to be between RMB 23 million and RMB 29 million, representing a year-on-year decline of 55.93% to 44.43% compared to RMB 52.19 million in the same period last year[3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between RMB 18 million and RMB 24 million, a decrease of 28.57% to 4.76% from RMB 25.20 million in the previous year[3]. - The basic earnings per share are expected to be between RMB 0.07 and RMB 0.09, down from RMB 0.17 in the same period last year[3]. - The company's operating revenue decreased by approximately RMB 114 million, a decline of around 18%, primarily due to a further drop in product prices despite stable sales volume[4]. Non-Recurring Items - Non-recurring gains and losses for the reporting period are expected to be around RMB 5 million, a decrease of approximately RMB 22 million year-on-year, mainly due to fair value losses on securities investments[5]. - The company has incurred share-based payment expenses of approximately RMB 4.5 million during the reporting period, net of deferred income tax[5]. Cautionary Notes - The financial data presented in the earnings forecast has not been audited by an accounting firm[4]. - The company advises investors to make cautious decisions and be aware of investment risks as the earnings forecast is a preliminary estimate[6].